TickerFacts.

Company research / PCRX

Pacira BioSciences, Inc. (PCRX)

Build a valuation ↗↓ Download CSV

CIK 0001396814 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Pacira BioSciences, Inc. reported revenue of $726.41M. Revenue grew 3.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $746.16M.

Key ratios (year ended 2025-12-31)

79.4%
Gross margin (computed)
2.6%
Operating margin
1.0%
Net margin
1.0%
Return on year-end equity
3.6%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-09

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$746.16M$726.41M$700.97M$674.98M$666.82M$541.53M$429.65M$418.93M$332.43M$284.34M$270.07M
Cost of Revenue$155.15M$149.75M$170.43M$184.67M$199.29M$140.25M$117.33M$106.71M$86.84M$87.92M$110.10M
Gross Profit (computed)$591.01M$576.66M$530.54M$490.31M$467.53M$401.28M$312.32M$312.21M$245.58M$196.43M$159.97M
R&D Expense$121.73M$117.31M$81.58M$76.26M$84.80M$55.55M$59.42M$72.12M$55.69M$57.29M$45.68M
Operating Income$19.87M$19.19M-$73.37M$87.67M$60.02M$89.92M$46.35M$10.48M$15.91M-$24.94M-$32.02M
Depreciation & Amortization$85.16M$91.02M$78.78M$75.57M$91.50M$28.55M$19.91M$19.58M$13.16M$13.83M$12.92M
EBITDA$105.03M$110.21M$5.41M$163.25M$151.53M$118.47M$66.26M$30.06M$29.08M-$11.10M-$19.11M
Net Income$14.64M$7.03M-$99.56M$41.95M$15.91M$41.98M$145.52M-$11.02M-$471.0K-$42.61M-$37.95M
EPS (Diluted)n/a$0.16-$2.15$0.89$0.34$0.92$3.33-$0.27-$0.01-$1.07-$1.02
Total Assets$1.24B$1.26B$1.55B$1.57B$1.68B$2.08B$1.27B$831.07M$689.35M$628.37M$391.47M
Total Liabilities$572.00M$571.81M$775.17M$704.26M$906.19M$1.34B$654.83M$476.12M$368.13M$348.89M$172.49M
Long-Term Debt$363.12M$372.19M$585.32M$522.44M$689.47Mn/an/an/an/an/a$108.74M
Shareholders' Equity$671.98M$693.11M$778.35M$870.13M$775.01M$730.41M$619.69M$354.94M$321.23M$279.48M$218.98M
Cash & Equivalents$205.88M$158.54M$276.77M$153.30M$104.14M$585.58M$99.96M$78.23M$132.53M$54.13M$35.94M
Operating Cash Flow$187.66M$151.99M$189.39M$154.65M$145.27M$125.72M$77.03M$70.52M$48.87M$17.79M$33.45M
Capital Expenditures$8.15M$15.33M$10.64M$15.16M$30.08M$45.87M$37.80M$10.16M$14.51M$19.27M$24.71M
Free Cash Flow$179.51M$136.66M$178.75M$139.49M$115.20M$79.85M$39.23M$60.36M$34.36M-$1.48M$8.74M
Share Repurchases$148.33M$148.33M$25.00M$0$0n/an/an/an/an/an/a
Shares Outstanding39.82M41.12M46.24M46.48M45.93M44.73M43.64M41.91M41.22M40.67M37.48M
Weighted Average Diluted Sharesn/a45.04M46.24M51.98M46.54M45.63M43.68M41.51M40.91M39.81M37.24M
EPS (Basic)n/a$0.16-$2.15$0.91$0.35$0.95$3.41-$0.27-$0.01-$1.07-$1.02

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView